SCHEMBL22323629

SCHEMBL22323629

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COc2cc(CCC(=O)c3ccccc3C(=O)O)ccc2C(=O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNMT Q14749 4/20 0.56
ADORA1 P30542 3/20 0.54
TRPM2 O94759 2/20 0.54
DNPH1 O43598 1/20 0.52
PRKAB2 O43741 1/20 0.52
LDHA P00338 1/20 0.52
ADRB2 P07550 1/20 0.52
FBP1 P09467 1/20 0.52
SRC P12931 1/20 0.52
P2RY2 P41231 1/20 0.52
P2RY1 P47900 1/20 0.52
PRKAG1 P54619 1/20 0.52
PRKAA2 P54646 1/20 0.52
PDE4D Q08499 1/20 0.52
KCNH2 Q12809 1/20 0.52
PRKAA1 Q13131 1/20 0.52
PDE3A Q14432 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TAS1R3 Q7RTX0 1/20 0.52
TAS1R1 Q7RTX1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22343548 0.94 ADORA1 (0.52) GNMTADORA1TRPM2
SCHEMBL29702967 0.94 ADORA1 (0.52) GNMTADORA1TRPM2
SCHEMBL22343666 0.92 GNMT (0.56) GNMTADORA1TRPM2DNPH1PRKAB2
SCHEMBL22343533 0.90 GNMT (0.57) GNMTADORA1TRPM2NT5E
SCHEMBL22343635 0.87 BCHE (0.46) GNMTNT5E
SCHEMBL29702996 0.87 ADORA1 (0.54) GNMTADORA1TRPM2DNPH1PRKAB2
SCHEMBL22343675 0.87 ADH1A (0.53) GNMTADORA1TRPM2DNPH1PRKAB2
SCHEMBL22343764 0.84 ADORA1 (0.54) GNMTADORA1TRPM2NT5E
SCHEMBL22343634 0.84 AHCY (0.45) GNMTNT5E
SCHEMBL22343636 0.82 BCHE (0.45) GNMTNT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220235088-A1 INHIBITORS OF ADENYLATE-FORMING ENZYME MENE MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2022-07-28 US disclosed
EP-3921324-A1 INHIBITORS OF ADENYLATE-FORMING ENZYME MENE Memorial Sloan Kettering Cancer Center (US) 2021-12-15 EP disclosed
WO-2020163673-A1 INHIBITORS OF ADENYLATE-FORMING ENZYME MENE MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2020-08-13 WO disclosed
WO-2020163673-A1 INHIBITORS OF ADENYLATE-FORMING ENZYME MENE MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235088-A1 INHIBITORS OF ADENYLATE-FORMING ENZYME MENE ADSL, MEN1, AMD1 GNMT 526/4885ADORA1 309/4885TRPM2 2129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.